Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 87 clinical trials
featured
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

Gene transfer is a new cancer therapy takes white blood cells from a person and grows them in a lab. The cells are changed with a virus to attack tumor cells, then returned to the person. Researchers want to see if this therapy fights kidney cancer cells. Metastatic renal cell …

carcinoma
primary cancer
clear cell renal cell carcinoma
renal cell cancer
metastatic cancer
  • 144 views
  • 22 Dec, 2020
  • 1 location
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer

The purpose of this study is to evaluate the safety and time to progression of HLA-A*0201 restricted epitope peptides URLC10, VEGFR1 and VEGFR2 emulsified with Montanide ISA 51.

VEGFR2
platelet count
  • 32 views
  • 07 Nov, 2020
  • 1 location
Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer

The purpose of this study is to evaluate the safety and time to progression of HLA-A*2402 restricted epitope peptides URLC10, TTK and KOC1 emulsified with Montanide ISA 51.

platelet count
  • 15 views
  • 07 Nov, 2020
  • 1 location
Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent Locally Advanced or Metastatic Solid Tumors

with atezolizumab or other immune checkpoint inhibitors in HLA-A*02+ patients with recurrent, locally advanced or metastatic human papillomavirus strain 16 positive (HPV16+) solid tumors. The study

measurable disease
solid tumour
cancer
  • 6 views
  • 31 Jul, 2021
  • 12 locations
The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia

(Thymoglobuline, Genzyme) 3.5mg/kg/d5d plus oral cyclosporine A (CSA) Cord blood transfusion group: In addition to the same dose and course of ATG and CSA , one unit of cord blood having no more than 2 HLA-A, B

cyclosporine oral product
paroxysmal nocturnal hemoglobinuria
thymoglobulin
cyclosporine
immunosuppression
  • 13 views
  • 24 Jan, 2021
  • 1 location
Intra Bone Marrow Injection Of Unrelated Cord Blood Cells

Compared to other stemcell sources cord blood (CB) is easier and safer to procure, has no donor attrition, a limitless supply, reduced viral transmission, less acute & chronic GVHD, is rich in hematopoietic progenitor cells, and immaturity of T-cell-mediated immunity. CB has delayed neutrophil and platelet engraftment, a prolonged immune …

hematologic malignancy
anemia
graft versus host disease
neutrophil count
cancer
  • 15 views
  • 07 Nov, 2020
  • 1 location
EBV-TCR-T Cells for EB Virus Infection After HSCT

This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of EBV-TCR-T cells in patients with EB virus infection after HSCT.

  • 0 views
  • 24 Jan, 2021
  • 1 location
CMV-TCR-T Cells for CM Virus Infection After HSCT

This is a single cente, single arm, open-label, phase I study to evaluate the safety and effectiveness of CMV-TCR-T cell immunotherapy in treating CMV virus infection after HSCT.

  • 0 views
  • 17 Feb, 2021
  • 2 locations
Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer

The purpose of this study is to evaluate the safety and immune response of multiple peptides (URLC10, TTK, KOC1 VEGFR1, and VEGFR2) emulsified with Montanide ISA51 in combination with chemotherapy (CDDP, 5-FU) plus radiation therapy in treating patients with unresectable, advanced or recurrent esophageal cancer.

recurrent esophageal cancer
measurable disease
chemoradiotherapy
ct scan
platelet count
  • 11 views
  • 07 Nov, 2020
  • 1 location
Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies

The experimental treatment consists in the application of a therapeutic strategy with post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatched (7/8 matched) Unrelated Hemopoietic Stem Cell Transplantation for Myeloid Malignancies.

  • 0 views
  • 26 Mar, 2021
  • 33 locations